SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Apr. 30, 2024	Apr. 30, 2023	Apr. 30, 2024	Apr. 30, 2023	Oct. 31, 2023
Segment Reporting Information [Line Items]
Net loss	$ (3,180)	$ (2,307)	$ (6,470)	$ (4,661)
Total operating costs and expenses	3,467	2,770	7,076	5,326
Less non-cash stock-based compensation	(1,260)	(1,227)	(2,520)	(2,290)
Operating costs and expenses excluding non-cash share based compensation	2,207	1,543	4,556	3,036
Total assets	24,355		24,355		$ 25,522
CAR-T Therapeutics [Member]
Segment Reporting Information [Line Items]
Net loss	(1,444)	(997)	(2,970)	(1,908)
Operating costs and expenses excluding non-cash share based compensation	1,026	620	2,154	1,218
Total assets	11,314		11,314		7,523
Cancer Vaccines [Member]
Segment Reporting Information [Line Items]
Net loss	(1,713)	(913)	(3,469)	(1,871)
Operating costs and expenses excluding non-cash share based compensation	1,160	523	2,373	1,111
Total assets	12,778		12,778		17,215
Other [Member]
Segment Reporting Information [Line Items]
Net loss	(23)	(397)	(31)	(882)
Operating costs and expenses excluding non-cash share based compensation	21	$ 400	29	$ 707
Total assets	$ 263		$ 263		$ 784